Novartis Takes Its IL-6 Antibody Into Phase 3 After Novo's Miss

At the European Society of Cardiology congress in Munich, Novartis said it will begin a Phase 3 trial testing whether its anti-IL-6 antibody can prevent cardiovascular events in people with elevated cardiovascular risk by lowering inflammation, proceeding despite the failure of Novo Nordisk's rival effort.

Novartis AG (NVS) used the European Society of Cardiology congress in Munich to confirm that it is pressing on with the most contested idea in cardiovascular medicine: that quieting inflammation, rather than lowering cholesterol or blood pressure, can stop heart attacks and strokes. The company said it will begin a Phase 3 trial of its anti–interleukin-6 antibody in people with elevated cardiovascular risk, testing whether damping inflammatory signalling translates into fewer cardiovascular events.

The decision is notable for its timing. It comes after the failure of Novo Nordisk A/S (NVO) in the same mechanism — a setback that many in the field read as a verdict on the whole anti-IL-6 approach to heart disease rather than on one molecule. Novartis is arguing, in effect, that the mechanism was not the problem.

What the trial is actually asking

Interleukin-6, or IL-6, is a signalling protein the body releases as part of the inflammatory response. In cardiology, the interest in blocking it rests on a simple chain of reasoning: atherosclerosis is an inflammatory disease of the artery wall, patients with high inflammatory markers suffer more events even when their cholesterol is controlled, and so a drug that suppresses the inflammatory signal should reduce that residual risk.

Proving it is the hard part. A cardiovascular outcomes trial is not a biomarker study. It has to show that a measurable biological effect — less inflammation — turns into fewer heart attacks, strokes and cardiovascular deaths in a population that is already, in most cases, receiving statins and other standard therapy. That means large patient numbers, long follow-up, and a population selected carefully enough that enough events occur to read the result.

Novartis has described the trial as enrolling people with elevated cardiovascular risk and testing prevention of cardiovascular events through reduced inflammation, as Endpoints News reported from Munich. The company has not, on the basis of what was presented, laid out a case that its antibody works differently in kind from Novo's; the bet is that execution, population and dosing decide the outcome.

Why Novo's failure did not end the thesis

Drug developers distinguish sharply between a failed molecule and a failed mechanism, and the distinction is where all the remaining value in this field sits. If Novo's result showed that blocking IL-6 simply does not move cardiovascular outcomes, then Novartis is spending several years and a great deal of money to confirm a negative. If instead the failure came down to the patient population enrolled, the level of inflammation at baseline, the degree of suppression achieved, the duration of exposure, or the amount of competing risk in the trial, then the mechanism remains open and the first company to demonstrate it wins a category on its own.

That is not a naive position. Cardiovascular medicine has a history of mechanisms that looked dead until a better-designed trial resurrected them, and of classes where the second or third entrant produced the definitive outcomes data. It is also, unavoidably, an expensive position. Outcomes trials in prevention are among the costliest studies in the industry, and the read-out is binary in a way that oncology data rarely is.

The commercial stakes on both sides

For Novartis, cardiovascular disease has been a deliberate strategic priority alongside oncology and immunology, and a successful anti-inflammatory prevention drug would address a population measured in tens of millions rather than thousands. The catch is that prevention markets reward proof, not plausibility: payers in the United States and Europe have grown unwilling to fund expensive biologics for risk reduction without hard event data, and physicians treating asymptomatic patients need a strong number to justify an injectable on top of existing therapy.

For Novo Nordisk, the failure removes an intended diversification away from its dominance in obesity and diabetes — a dependence investors have flagged repeatedly. Watching a competitor take the same mechanism forward is an uncomfortable position: a Novartis success would validate the science Novo abandoned, while a second failure would at least settle the question.

How the shares sit going in

Neither stock reflects much drama from Munich. Novartis last closed at 153.81, down 0.54% on the day, having traded in a 152.77–154.56 range, against a prior close of 154.65. Novo Nordisk last closed at 45.61, down 1.41%, with a 45.41–46.21 range and a prior close of 46.26. Both figures are as of the last trade on Friday, 28 August 2026 at 20:00 GMT; the market is closed.

The backdrop was soft rather than disorderly. The S&P 500, via the SPY tracker, closed at $769.35, down 0.23%. The Nasdaq 100 proxy QQQ closed at $716.43, down 0.65%. The Dow tracker DIA finished at $535.06, down 0.03%. In other words, the moves in both pharma names sit within a market-wide drift, which is the normal pattern for a trial start: Phase 3 initiations rarely reprice a large-cap drugmaker, because the cash outlay is known and the pay-off is years away.

What to watch from here

Three things will determine whether this becomes a genuine catalyst. First, the enrolment criteria — specifically how the trial defines elevated cardiovascular risk and whether it screens for a raised inflammatory marker, which is the single design choice most likely to separate Novartis's result from Novo's. Second, the size and expected event rate, which set how long the study must run before an independent committee can look at the data. Third, any interim analysis, since a futility read-out would land on the stock long before the primary result.

Until then, the story is a scientific one with an option attached. Novartis is paying for the option; Novo Nordisk has already written its own off. The outcomes data, whenever it arrives, will tell the market which company read the failure correctly.

Key facts

• Novartis (NVS) last close: 153.81, -0.54% (as of 28 Aug 2026, 20:00 GMT)
• Novo Nordisk (NVO) last close: 45.61, -1.41% (as of 28 Aug 2026, 20:00 GMT)
• Trial stage: Phase 3 start, anti-IL-6 antibody, elevated cardiovascular risk
• Venue: European Society of Cardiology congress, Munich

Frequently asked questions

What did Novartis announce in Munich?

At the European Society of Cardiology congress, Novartis said it will start a Phase 3 trial of its anti-IL-6 antibody. The study will test whether reducing inflammation in people with elevated cardiovascular risk can prevent cardiovascular events such as heart attacks and strokes. The company is proceeding despite the failure of Novo Nordisk's rival effort in the same mechanism.

What is IL-6 and why does it matter in heart disease?

Interleukin-6 is a signalling protein released during the body's inflammatory response. Atherosclerosis, the build-up of plaque in artery walls, is partly an inflammatory disease, and patients with high inflammatory markers suffer more cardiovascular events even when cholesterol is controlled. Blocking IL-6 is meant to reduce that residual inflammatory risk on top of standard therapy.

Why is Novartis continuing after Novo Nordisk failed?

Drug developers separate a failed molecule from a failed mechanism. Novartis's position implies the failure may have stemmed from trial design choices — the patient population, baseline inflammation levels, dosing or follow-up duration — rather than from IL-6 being the wrong target. If that reading is right, the mechanism remains commercially open.

How did the two stocks close?

As of the last trade on 28 August 2026 at 20:00 GMT, Novartis closed at 153.81, down 0.54% from a prior close of 154.65, in a 152.77–154.56 range. Novo Nordisk closed at 45.61, down 1.41% from 46.26, in a 45.41–46.21 range. Both moves sat within a broadly softer market.

Why didn't the shares move much on the news?

Phase 3 initiations rarely reprice large-cap drugmakers. The spending is largely known and budgeted, while the pay-off depends on outcomes data years away. Broad indices were also lower on the day — the S&P 500 tracker fell 0.23% and the Nasdaq 100 proxy 0.65% — so both pharma moves fit a market-wide drift.

What are the next milestones to watch?

The enrolment criteria matter most, particularly whether patients must show a raised inflammatory marker to qualify. After that, the trial's size and expected event rate determine how long it must run, and any planned interim analysis could produce an early signal — including a futility read-out — well before the primary result.

Sources

• #ESC26: Novartis pushes ahead with its IL-6 inhibitor despite Novo's failure — Endpoints News

Photo: Towfiqu barbhuiya · Pexels Licence — source